Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
MicroTech Medical (Hangzhou) Co., Ltd. Class H ( (HK:2235) ) just unveiled an update.
MicroTech Medical reported a substantial increase in its financial performance for the first half of 2025, with operating revenue rising by 63.1% to RMB245.93 million and gross profit increasing by 57.7% to RMB127.04 million. This growth was driven by a 91.5% increase in CGMS sales, both domestically and internationally. The company also significantly reduced its net loss by 93.9% to RMB2.29 million, attributed to expanded sales, improved budget control, and enhanced operational efficiency. Cost-reducing measures led to a notable decrease in selling and administrative expenses relative to revenue, and the company maintained strong cash reserves of RMB1.716 billion.
The most recent analyst rating on (HK:2235) stock is a Sell with a HK$5.50 price target. To see the full list of analyst forecasts on MicroTech Medical (Hangzhou) Co., Ltd. Class H stock, see the HK:2235 Stock Forecast page.
More about MicroTech Medical (Hangzhou) Co., Ltd. Class H
MicroTech Medical (Hangzhou) Co., Ltd. is a company incorporated in the People’s Republic of China, operating in the medical technology industry. The company focuses on the development, production, and commercialization of core pipeline products, with a significant emphasis on continuous glucose monitoring systems (CGMS).
Average Trading Volume: 255,093
Technical Sentiment Signal: Buy
Current Market Cap: HK$3.13B
For detailed information about 2235 stock, go to TipRanks’ Stock Analysis page.